FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATION.

B Conclusions: b An MRD-driven strategy allows ibrutinib discontinuation in indolent clinical forms of MCL patients who persist with prolonged MRD and also clinical responses. At current follow-up, 6 patients remain on treatment, and up to 13 patients discontinued ibrutinib because of adverse events, including 7 associated to ibrutinib with a hemorrhagic cardiac tamponade being the most severe. [Extracted from the article]